Document Detail

Desmoteplase: discovery, insights and opportunities for ischaemic stroke.
MedLine Citation:
PMID:  21627637     Owner:  NLM     Status:  MEDLINE    
Nature has provided a vast array of bioactive compounds that have been exploited for either diagnostic or therapeutic use. The field of thrombosis and haemostasis in particular has enjoyed much benefit from compounds derived from nature, notably from snakes and blood-feeding animals. Indeed, the likelihood that blood-feeding animals would harbour reagents with relevant pharmacology and with potential pharmaceutical benefit in haemostasis was not too far-fetched. Blood-feeding animals including leeches and ticks have evolved a means to keep blood from clotting or to at least maintain the liquid state, and some of these have been the subject of clinical development. A more recent example of this has been the saliva of the common vampire bat Desmodus rotundus, which has proven to harbour a veritable treasure trove of novel regulatory molecules. Among the bioactive compounds present is a fibrinolytic compound that was shown over 40 years ago to be a potent plasminogen activator. Studies of this vampire bat-derived plasminogen activator, more recently referred to as desmoteplase, revealed that this protease shared a number of structural and functional similarities to the human fibrinolytic protease, tissue-type plasminogen activator (t-PA) yet harboured critically important differences that have rendered this molecule attractive for clinical development for patients with ischaemic stroke.
Robert L Medcalf
Related Documents :
16178637 - Effects of skin on bias and reproducibility of near-infrared spectroscopy measurement o...
8117847 - Control of skin blood flow in pre- and full-term infants.
1947447 - Gas exchange in isolated perfused frog skin as a function of perfusion rate.
17675187 - The effect of glibenclamide on cutaneous laser-doppler flux.
23566997 - Performance of a new meter designed for assisted monitoring of blood glucose and point-...
12790417 - A modified protocol for sex identification of in ovo avian embryos and its application ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of pharmacology     Volume:  165     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-07     Completed Date:  2012-06-05     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  75-89     Citation Subset:  IM    
Copyright Information:
© 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Australian Centre for Blood Diseases, Monash University, 89 Commercial Road, Melbourne, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrinolytic Agents / chemistry*,  therapeutic use*
Plasminogen Activators / chemistry*,  therapeutic use*
Saliva / chemistry
Stroke / drug therapy*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/salivary plasminogen activator alpha 1, Desmodus rotundus; EC 3.4.21.-/Plasminogen Activators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Opioids and the immune system: what is their mechanism of action?
Next Document:  Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the ro...